Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of April 5, 2025 • 7:00 PM ET

Date/Time Source News Release
03/26/2025 08:15 AM EDT PR Newswire Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
03/25/2025 08:15 AM EDT PR Newswire Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
03/04/2025 08:15 AM EST PR Newswire Genprex to Participate at BIO Europe Spring 2025
02/19/2025 08:15 AM EST PR Newswire Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System
02/18/2025 08:15 AM EST PR Newswire Genprex Provides Update on Diabetes Gene Therapy Program
02/13/2025 08:15 AM EST PR Newswire Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer
01/23/2025 08:00 AM EST PR Newswire Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
01/06/2025 09:15 AM EST PR Newswire Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
12/16/2024 09:15 AM EST PR Newswire Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer
11/20/2024 09:29 AM EST PR Newswire Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer
Page

Additional News

As of April 5, 2025 • 7:00 PM ET

Date/Time Source News Release
11/23/2024 04:40 AM EST US Earnings Reports Expected earnings - Genprex Inc.
10/28/2024 04:30 PM EDT QM US Market Movers News US Companies Moving the Markets, Evening edition
Mon, Oct 28, 2024 as of 4:00 pm ET
10/23/2024 10:00 AM EDT QM US Market Movers News US Companies Moving the Markets, Morning edition
Wed, Oct 23, 2024 as of 10.00 am ET
10/22/2024 04:30 PM EDT QM US Market Movers News US Companies Moving the Markets, Evening edition
Tue, Oct 22, 2024 as of 4:00 pm ET
10/22/2024 11:11 AM EDT InvestorBrandNetwork Genprex Inc. (NASDAQ: GNPX) is One of Tuesday Morning's Most Active Stocks
10/22/2024 10:01 AM EDT QM US Market Movers News US Companies Moving the Markets, Morning edition
Tue, Oct 22, 2024 as of 10.00 am ET
10/21/2024 04:30 PM EDT QM US Market Movers News US Companies Moving the Markets, Evening edition
Mon, Oct 21, 2024 as of 4:00 pm ET
10/21/2024 02:42 PM EDT 24/7 Market News The MoBot Report
10/21/2024 10:00 AM EDT QM US Market Movers News US Companies Moving the Markets, Morning edition
Mon, Oct 21, 2024 as of 10.00 am ET
08/14/2024 02:27 PM EDT SeekingAlpha Genprex stock slides 14% following Reqorsa study updates
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.